Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (461-470 of 607) with videos related to

Pageof 61
Sort By:
The Lancet. Rheumatology|October 17, 2025
Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosisJohn D Pauling, Yannick Allanore, Maya H Buch, et al.
Rheumatology (Oxford, England)|February 5, 2025
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosisChristopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, et al.
Arthritis and Rheumatism|February 2, 2008
Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblastsYunliang Chen, Andrew Leask, David J Abraham, et al.
The Lancet. Respiratory Medicine|November 14, 2022
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trialToby M Maher, Veronica A Tudor, Peter Saunders, et al.
Annals of the Rheumatic Diseases|May 18, 2010
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT groupJérôme Avouac, Otylia Kowal-Bielecka, David Pittrow, et al.
Arthritis Research & Therapy|June 25, 2011
Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are neededChristopher P Denton, Jerome Avouac, Frank Behrens, et al.
Rheumatology (Oxford, England)|June 11, 2016
BSR and BHPR guideline for the treatment of systemic sclerosisChristopher P Denton, Michael Hughes, Nataliya Gak, et al.
The FEBS Journal|July 7, 2025
Multi-omic analysis identifies biological processes underlying progressive interstitial lung disease in systemic sclerosisSelena Bouffette, Perrine Soret, Alice Cole, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2025
[<sup>18</sup>F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung DiseaseDavid M L Lilburn, Helen S Garthwaite, Balaji Ganeshan, et al.
Arthritis Research & Therapy|February 1, 2018
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR groupSabine Adler, Dörte Huscher, Elise Siegert, et al.
Pageof 61

Showing results (461-470 of 607) with videos related to

Sort By:
Pageof 61
The Lancet. Rheumatology|October 17, 2025
Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosisJohn D Pauling, Yannick Allanore, Maya H Buch, et al.
Rheumatology (Oxford, England)|February 5, 2025
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosisChristopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, et al.
Arthritis and Rheumatism|February 2, 2008
Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblastsYunliang Chen, Andrew Leask, David J Abraham, et al.
The Lancet. Respiratory Medicine|November 14, 2022
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trialToby M Maher, Veronica A Tudor, Peter Saunders, et al.
Annals of the Rheumatic Diseases|May 18, 2010
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT groupJérôme Avouac, Otylia Kowal-Bielecka, David Pittrow, et al.
Arthritis Research & Therapy|June 25, 2011
Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are neededChristopher P Denton, Jerome Avouac, Frank Behrens, et al.
Rheumatology (Oxford, England)|June 11, 2016
BSR and BHPR guideline for the treatment of systemic sclerosisChristopher P Denton, Michael Hughes, Nataliya Gak, et al.
The FEBS Journal|July 7, 2025
Multi-omic analysis identifies biological processes underlying progressive interstitial lung disease in systemic sclerosisSelena Bouffette, Perrine Soret, Alice Cole, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2025
[<sup>18</sup>F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung DiseaseDavid M L Lilburn, Helen S Garthwaite, Balaji Ganeshan, et al.
Arthritis Research & Therapy|February 1, 2018
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR groupSabine Adler, Dörte Huscher, Elise Siegert, et al.
Pageof 61